敗血症臓器障害におけるVEGFとアンジオポエチンの研究：短期型βブロッカーの作用

点击翻译按钮获取中文摘要

We completed 3 years of this research. With working on acute lung injury, we also did many experiments on LPS-induced myocardial dysfunction and liver injury. Morphologically, landiolol hydrochloride, an ultra-short-acting β-blocker, plays vital role in lessening LPS-induced cardiac and liver injury. We used male Wistar rats at 8 weeks of age and were administered with either saline or lipopolysaccharide (LPS) for three hours (3h), and some of the LPS-administered rats were continuously treated with landiolol for 3h, extending experiments for 6h and 10h. We have seen the changes in both circulatory and tissue TNF-α and IL-6 with alteration of level of angiopoietin-2 in heart and liver. These changes were accompanied an LPS-induced considerable alteration in cardiac and liver levels of VEGF with Pa02. Here we found that the treatment of LPS-administered rats with landiolol starting from 3h significantly stopped the progression of cardiac dysfunction and liver injury with marked normalization of angiopoietin-2. This treatment also considerably normalized blood gas parameters, and tissue VEGF levels. Collectively, our data indicate that landiolol treatment in LPS-administered rats plays an essential role in attenuating cardiac dysfunction and liver injury through modulation of angiopoietin-2 with concomitant VEGF signaling reversal.